Filing Flows › Starling Oncology (STLN) › Q2 2025
Starling Oncology (STLN) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 13, 2025
Starling Oncology (STLN) reported revenue of $120M for the second quarter 2025 (Q2 2025), +22% from a year earlier and +15% from the quarter before. Operating margin was -9.4%, net loss $17.0M (14.2% of revenue).
Starling Oncology, Q2 2025: revenue $120M (+22% year over year), operating margin -9.4%, net loss $17.0M, operating cash flow −$10.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $120M | +15% | +22% |
| Operating profit | −$11.2M | — | — |
| Net earnings | −$17.0M | — | — |
| Operating cash flow | −$10.2M | — | — |
What changed
Revenue was $119.8M in Q2 2025, up 22% year over year and up 15% from the previous quarter. Dispensary was the largest line at 52% of revenue. Dispensary added $18.1M year over year (up 41%), 85% of the total change. Clinical trials & other declined 20%.
Operating costs exceeded revenue by $11.2M, an operating margin of -9.4%. Total costs grew 14% against revenue growth of 22%. The fastest-growing cost line was Other operating costs (+20%). The quarter ended with a net loss of $17.0M, narrower than the previous quarter's $19.6M loss.
Operating cash flow was −$10.2M. Non-cash charges added back $1.8M of depreciation and amortization and $752K of share-based compensation. Working capital and other items added $4.2M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$11.4M.
Questions
What was Starling Oncology's revenue in the second quarter 2025?
Starling Oncology (STLN) reported revenue of $120M for the second quarter 2025 (Q2 2025), +22% from a year earlier and +15% from the quarter before.
Was Starling Oncology profitable in the second quarter 2025?
Operating loss was $11.2M (-9.4% of revenue) and net loss $17.0M.
Source: Starling Oncology 10-Q on SEC EDGAR.